Why was Bryan Ball’s Whitehawk Therapeutics (WHWK) share sale executed?

The sale was executed to cover tax withholding on vested RSUs. A broker-assisted transaction sold 1,834 common shares, as disclosed in the footnotes, rather than representing a discretionary open-market reduction of Bryan Ball’s personal investment in Whitehawk Therapeutics.

Whitehawk Therapeutics (WHWK) officer vests 5,000 RSUs, small tax sale

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Whitehawk Therapeutics officer Bryan Ball reported routine equity compensation activity. On March 1, 2026, he exercised restricted stock units, acquiring 5,000 shares of Common Stock at a conversion price of $0.00 per share, increasing his direct holdings.

On March 2, 2026, Ball disposed of 1,834 shares of Common Stock at an average price of $3.3096 per share in a broker-assisted transaction used to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he directly held 206,019 shares of Common Stock and 10,000 Restricted Stock Units.

Insider Trade Summary

Net Seller: 1,834 shares ($6,070)

Net Sell 3 txns

Insider BALL BRYAN

Role See remarks

Sold 1,834 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,834	$3.3096	$6K
Exercise	Restricted Stock Units	5,000	$0.00	--
Exercise	Common Stock	5,000	$0.00	--

Holdings After Transaction: Common Stock — 206,019 shares (Direct); Restricted Stock Units — 10,000 shares (Direct)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.

Form 4 Insider Transactions: What Each Field Means →

03/10/2026 - 07:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BALL BRYAN

(Last)

(First)

(Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN

07960

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/01/2026		M		5,000	A	⁽¹⁾	207,853	D
Common Stock	03/02/2026		S⁽²⁾		1,834	D	$3.3096	206,019	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/01/2026		M			5,000	⁽³⁾	⁽³⁾	Common Stock	5,000	$0	10,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

2. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.

Remarks:

Chief Technical Operations Officer and SVP, Manufacturing Operations

	/s/ Stephen Rodin, as Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Whitehawk Therapeutics (WHWK) officer Bryan Ball report in this Form 4?

Bryan Ball reported RSU-related activity and a small share sale. He exercised 5,000 restricted stock units into common stock, then sold 1,834 shares to cover tax withholding tied to the vesting, while keeping a larger equity position.

How many Whitehawk Therapeutics (WHWK) shares did Bryan Ball sell and at what price?

Bryan Ball disposed of 1,834 shares of Whitehawk Therapeutics common stock. The broker-assisted sale occurred at an average price of $3.3096 per share and was specifically used to satisfy tax withholding obligations from his RSU vesting.

How many Whitehawk Therapeutics (WHWK) shares does Bryan Ball hold after these transactions?

Following the reported transactions, Bryan Ball directly holds 206,019 shares of Whitehawk Therapeutics common stock. In addition, he has 10,000 restricted stock units outstanding, each representing a contingent right to receive one additional share upon future vesting.

What happened to Bryan Ball’s restricted stock units in Whitehawk Therapeutics (WHWK)?

5,000 restricted stock units converted into common shares at a $0.00 conversion price. Each RSU equals one common share. After this vesting and exercise event, Bryan Ball still has 10,000 RSUs outstanding, which are scheduled to vest over future anniversary dates.

How do Bryan Ball’s restricted stock units in Whitehawk Therapeutics (WHWK) vest over time?

The RSUs vest in four equal annual installments starting March 1, 2025. Twenty-five percent of the award vests on each anniversary of the March 1, 2024 vesting commencement date, contingent on Bryan Ball continuing as a service provider to Whitehawk Therapeutics.